Literature DB >> 20413586

No ticking time bomb: hospital utilisation of 28,528 hip fracture patients in Stockholm during 1998-2007.

S Löfgren1, G Ljunggren, M Brommels.   

Abstract

AIM: The objectives were to show how utilisation of hospital care among hip fracture patients has changed in Stockholm during 1998-2007 and to explore changes in some demographic and clinical characteristics as well as surgical treatment of the patients.
METHODS: The Stockholm County Patient Care Register covers all public healthcare services in the region. All patients from 1998 to 2007 who had a hospital stay due to a hip fracture (ICD-10 codes S72.0, S72.1, S72.2) and had undergone hip surgery (NCSP codes NFB09-99 and NFJ39-99) were identified. Number of hospital stays, surgical procedures, deaths, and length of hospital stay were categorised according to age and sex, and presented as absolute and relative numbers year by year. Age- and sex-standardised annual incidence figures were calculated.
RESULTS: A total of 28,528 patients (72.2% women, 27.8% men) were hospitalised due to a hip fracture. The annual numbers decreased during the study period in all age groups except men 85 years and older. The age- and sex-standardised hip fracture incidence fell with 16%. Mortality was slightly reduced. The acute care hospital length of stay fell with 1.4 days to 7.0 days, and the whole hospital episode increased by 1.4 days to 17.3 days.
CONCLUSIONS: Despite a continued increase in the numbers of elderly during 1998-2007, the number of patients and their utilisation of hospital services remained constant and showed a marked decrease in women over 65 years of age. Comparisons with national statistics indicate that the results can be generalised to Sweden.

Entities:  

Mesh:

Year:  2010        PMID: 20413586     DOI: 10.1177/1403494810370232

Source DB:  PubMed          Journal:  Scand J Public Health        ISSN: 1403-4948            Impact factor:   3.021


  7 in total

1.  Predictors of hip fracture mortality in Ghana: a single-center prospective study.

Authors:  Paa Kwesi Baidoo; James B Odei; Velarie Ansu; Michael Segbefia; Henry Holdbrook-Smith
Journal:  Arch Osteoporos       Date:  2021-02-20       Impact factor: 2.617

2.  Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden.

Authors:  Carola Bardage; Ingemar Persson; Ake Ortqvist; Ulf Bergman; Jonas F Ludvigsson; Fredrik Granath
Journal:  BMJ       Date:  2011-10-12

3.  Total hospital stay for hip fracture: measuring the variations due to pre-fracture residence, rehabilitation, complications and comorbidities.

Authors:  Anthony W Ireland; Patrick J Kelly; Robert G Cumming
Journal:  BMC Health Serv Res       Date:  2015-01-22       Impact factor: 2.655

4.  Trends in Hip Fracture Incidence, Recurrence, and Survival by Education and Comorbidity: A Swedish Register-based Study.

Authors:  Anna C Meyer; Stina Ek; Sven Drefahl; Anders Ahlbom; Margareta Hedström; Karin Modig
Journal:  Epidemiology       Date:  2021-05-01       Impact factor: 4.860

5.  Sex effects on short-term complications after hip fracture: a prospective cohort study.

Authors:  Wilhelmina Ekström; Bodil Samuelsson; Sari Ponzer; Tommy Cederholm; Karl-Göran Thorngren; Margareta Hedström
Journal:  Clin Interv Aging       Date:  2015-08-05       Impact factor: 4.458

6.  Unpacking the key components of a programme to improve the timeliness of hip-fracture care: a mixed-methods case study.

Authors:  Pamela Mazzocato; Maria Unbeck; Mattias Elg; Olof Gustaf Sköldenberg; Johan Thor
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2015-11-09       Impact factor: 2.953

7.  High prevalence of diagnosis of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden - a challenge for public health.

Authors:  Axel C Carlsson; Per Wändell; Urban Ösby; Ramin Zarrinkoub; Björn Wettermark; Gunnar Ljunggren
Journal:  BMC Public Health       Date:  2013-07-18       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.